Kalaris Therapeutics Begins Enrollment for Phase 1b/2 Study of TH103 in Neovascular Age-Related Macular Degeneration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Source: Globenewswire
Phase 1b/2 Study Initiation: Kalaris Therapeutics has begun enrolling patients for a Phase 1b/2 multiple ascending dose study of TH103, aimed at assessing safety and efficacy in neovascular age-related macular degeneration (nAMD) patients, with initial data expected in the second half of 2026.
Ongoing Research and Development: The company is also on track to report data from its Phase 1a single ascending dose study in Q4 2025, which will inform the development of TH103, a novel therapy designed to enhance anti-VEGF activity for treating retinal diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
